Commercialisation
Research within the Inflammation Biology Group has significant potential to translate into real-world applications that improve patient outcomes and advance biomedical innovation. We work closely with the University of Birmingham’s commercialisation and technology transfer teams to protect intellectual property, support industry collaboration, and enable the development of new diagnostics, therapeutics, and research tools arising from our discoveries.
This page highlights our current patents, recent press activity relating to commercial outputs, and contact details for technology transfer enquiries.
List of current patents
PEPITEM
- Peptides & uses thereof – WO2014/104928
- Peptide agonist - WO2024/023535A1
- Bone disease treatment – US2024/0131110A1
- Treatment of obesity associated inflammatory conditions – WO2024/161123A1
- F. Maione, P. Greco, A.J. Iqbal, M. Bucci, F. Merlino, F. Raucci, A. Saviano & R. Bellavita (P022971IT-01)
- Novel interleukin-17A (IL-17A)-derived peptide and neutralizing antibody (Ab-IPL-IL-17)
Press releases
Adiponectin-PEPITEM
Adiponectin-PEPITEM
Bone
- New therapeutic avenues in bone repair - University of Birmingham
- Bone-Enhancing Peptide Shows Promise as Therapeutic for Osteoporosis and MSK Disorders (genengnews.com)
- Therapeutic potential for PEPITEM in osteoporosis - University of Birmingham
Obesity
- Naturally occurring immunopeptide may tackle the ‘root cause’ of obesity-related conditions | British Society for Immunology
- Novel peptide may tackle the root cause of type 2 diabetes
- Birmingham obesity research could herald novel therapy | Laboratory News
Psoriasis
IL-17 biologics
IL-17 biologics
Leukocyte Trafficking
Leukocyte Trafficking
Technology Transfer Officers contact details
For further media information please contact Ruth Ashton, University of Birmingham Enterprise, email: r.c.ashton@bham.ac.uk.
For enquiries about licensing or IP please contact Helen Dunster, University of Birmingham Enterprise, email: h.dunster@bham.ac.uk.